Table 1. Baseline Characteristics of Patients With NSCLC Treated With or Without TKIs After Propensity Score Matching.
| Characteristics | Patients, No. (%) | ASMD | |||||
|---|---|---|---|---|---|---|---|
| Total (n = 48 258) | TKI use (n = 24 129) | No TKI use (n = 24 129) | |||||
| Age, y | |||||||
| Mean (SD) | 66.93 (12.37) | 66.91 (11.92) | 66.95 (12.80) | 0.003 | |||
| Median (IQR) | 67.00 (18.00) | 67.00 (17.00) | 67.00 (19.00) | ||||
| Sex | |||||||
| Male | 24 043 (49.82) | 11 351 (47.04) | 12 692 (52.60) | 0.11 | |||
| Female | 24 215 (50.18) | 12 778 (52.96) | 11 437 (47.40) | ||||
| Therapies for cancer | |||||||
| Radiotherapy | 1438 (2.98) | 738 (3.06) | 700 (2.90) | 0.009 | |||
| Operations (lobectomy) | 2426 (5.03) | 1078 (4.47) | 1348 (5.59) | 0.05 | |||
| Anticancer drugsa | 10 707 (22.19) | 5653 (23.43) | 5054 (20.95) | 0.06 | |||
| Platinum analogues | 5219 (10.81) | 2600 (10.78) | 2619 (10.85) | 0.003 | |||
| Cardiovascular medications | |||||||
| ACEIs/ARBs | 13 242 (27.44) | 6537 (27.09) | 6705 (27.79) | 0.02 | |||
| β-blockers | 10 089 (20.91) | 4982 (20.65) | 5107 (21.17) | 0.01 | |||
| Anti-platelet agents | 7731 (16.02) | 3812 (15.80) | 3919 (16.24) | 0.01 | |||
| Anti-coagulants | 1382 (2.86) | 696 (2.88) | 686 (2.84) | 0.003 | |||
| Statins | 7440 (15.42) | 3621 (15.01) | 3819 (15.83) | 0.02 | |||
| Digoxin | 685 (1.42) | 348 (1.44) | 337 (1.40) | 0.004 | |||
| MRA | 1798 (3.73) | 908 (3.76) | 890 (3.69) | 0.004 | |||
| Antiarrhythmia drugsa | 1170 (2.42) | 583 (2.42) | 587 (2.43) | 0.001 | |||
| Comorbidities | |||||||
| Coronary artery disease | 5812 (12.04) | 2885 (11.96) | 2927 (12.13) | 0.005 | |||
| Peripheral artery disease | 926 (1.92) | 469 (1.94) | 457 (1.89) | 0.004 | |||
| Hypertension | 21 854 (45.29) | 10 837 (44.91) | 11 017 (45.66) | 0.02 | |||
| Diabetes mellitus | 10 458 (21.67) | 5168 (21.42) | 5290 (21.92) | 0.01 | |||
| Hyperlipidemia | 10 535 (21.83) | 5175 (21.45) | 5360 (22.21) | 0.02 | |||
| Valve diseases | 1336 (2.77) | 674 (2.79) | 662 (2.74) | 0.003 | |||
| Chronic obstructive pulmonary disease | 9741 (20.19) | 4721 (19.57) | 5020 (20.80) | 0.03 | |||
| Asthma | 3717 (7.70) | 1849 (7.66) | 18 68 (7.74) | 0.003 | |||
| Chronic kidney disease | 4171 (8.64) | 2001 (8.29) | 2170 (8.99) | 0.03 | |||
| End-stage kidney disease | 64 (0.13) | 32 (0.13) | 32 (0.13) | 0.000 | |||
Abbreviations: ASMD, absolute standardized mean difference; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; MRA, mineralocorticoid-receptor antagonists; NSCLC, non–small cell lung cancer; TKIs, tyrosine kinase inhibitors.
a
Anticancer drugs and antiarrhythmia drugs were listed in eTable 1 in Supplement 1.